Pharmaceutical Manufacturers Association
Executive Summary
Asks FDA Commissioner Kessler in July 31 letter to "withdraw" the Center for Drug Evaluation and Research's proposed policy to allow agency approval of indications over sponsors' objections. PMA contended that the policy, set forth in a Jan. 15 memo and expected to be published this month in the Federal Register ("The Pink Sheet" Aug. 3, p. 7), may discourage sponsors from pursuing early development of what they consider minor indications for fear that the agency will approve the minor indications and "relegate" major indications to efficacy supplements, which are perceived as being approved more slowly.
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.